OcuMension Therapeutics 3
3 · EyePoint Pharmaceuticals, Inc. · Filed Jan 14, 2021
Insider Transaction Report
Form 3
Ocumension Therapeutics
Director
Holdings
- 3,010,722
Common Stock, $0.001 par value
Signature
/s/ Matthew E. Johnson, attorney-in-fact for Ye Liu|2021-01-11